In two-way race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
In the two-man race to develop a new inhibitor for an aggressive form of lung cancer, Merck KGaA has won the first regulatory approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
